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Abstract We have evaluated the hypothesis that cGMP may
serve as an intracellular messenger regulating the viability of
pancreatic L-cells. A direct activator of soluble guanylyl cyclase,
YC-1, caused a time- and dose-dependent loss of viability in
clonal BRIN-BD11 L-cells. This was accompanied by a rise in
cGMP and was antagonised by Rp-8-pCPT-cGMPS, a selective
inhibitor of protein kinase G (PKG). Reverse transcription poly-
merase chain reaction analysis con¢rmed that BRIN-BD11 cells
(and human islets) express all three known isoforms of PKG
(PKG-IK, -IL and II). Cell death induced by YC-1 was not
sensitive to cell-permeable caspase inhibitors and was not ac-
companied by oligonucleosomal DNA fragmentation. The re-
sponse was, however, inhibited by actinomycin D, suggesting
that a transcription-dependent pathway of programmed cell
death is involved in the actions of cGMP.
/ 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The viability of pancreatic L-cells is regulated by a variety
of hormones, growth factors, metabolites and cytokines [1^3].
Some of these (e.g. IGF-1 [4] and mono-unsaturated fatty
acids [5,6]) actively protect L-cells from cytotoxicity, while
others (e.g. interleukin-IL and interferon-Q [1,2,7], saturated
fatty acids [5,6,8], Fas [7,9], hyperglycaemia [10,11]) directly
promote the loss of viability. Thus, under (patho)physiologi-
cal conditions, the long-term fate of the L-cells is determined
by the relative balance of these various factors and by the
activation state of the signalling systems they regulate.
Considerable e¡ort has been invested in understanding the
signalling pathways controlling L-cell viability and this work
has revealed that transcriptional regulation of multiple target
genes underlies the pro-apoptotic e¡ects of cytotoxic agents
[12^16]. However, the ‘upstream’ signalling events that control
L-cell apoptosis have proved more di⁄cult to de¢ne. In this
context, we previously reported that prolonged elevation of
cGMP is associated with entry of both rat [17] and human [7]
islet cells into apoptosis and proposed that cGMP may be a
hitherto unrecognised intracellular messenger involved in the
control of L-cell viability. This hypothesis is consistent with
data obtained in cardiomyocytes [18^21], retinal photorecep-
tors [22,23], lung [24], neutrophils [25] and arterial smooth
muscle [26] and was supported by the ¢ndings of others
[27,28] in L-cells. However, it was also reported that elevation
of cGMP can result in a mode of L-cell death that does not
always display the classical hallmarks of apoptosis [27].
In the majority of earlier work, either chemical NO donors
or cytokines acting to increase the expression of inducible NO
synthase were used to elevate cGMP in islet cells [17,27,28].
This is because a rise in NO leads to a secondary increase in
cGMP by promoting the activation of a soluble isoform of
guanylyl cyclase [29,30]. Such studies con¢rmed that elevation
of cGMP might be involved in mediating some of the cyto-
toxic e¡ects of NO donors and cytokines, and this conclusion
was supported by the observation that cell-permeable cGMP
analogues can also reduce viability [7,17,27]. However, the
results of experiments with cytokines or chemical NO donors
can be di⁄cult to interpret since NO is, itself, a highly reactive
radical that can inhibit metabolic enzymes and damage cellu-
lar DNA, thereby leading to cell death by pathways that do
not involve a rise in cGMP [31^33]. Moreover, treatment of
cells with chemical NO donors can often lead to the produc-
tion of other radical species (e.g. superoxide, peroxynitrite)
which may contribute to the cytotoxic e¡ects [34]. Thus, in
order to substantiate the involvement of cGMP in control of
L-cell viability, it is important that further studies are under-
taken with agents that lack these additional e¡ects.
In addition, a further important issue concerns the possible
involvement of cGMP-dependent protein kinase (PKG) in
mediating L-cell apoptosis. Earlier work implicated this en-
zyme in mediating the pro-apoptotic actions of cGMP but
was based largely on the use of a purportedly selective inhib-
itor, KT5823 [17,27,28]. This reagent has been employed
widely to study the activation of PKG in mammalian cells
but recent work has questioned the speci¢city and mode of
action of KT5823 [35,36]. Therefore, it is important that these
conclusions are re-evaluated by the use of a more speci¢c
PKG inhibitor.
In the present work, we have undertaken studies designed
to re-examine the involvement of cGMP and PKG in the
regulation of L-cell apoptosis. To achieve this, 1-benzyl-3-
(5P-hydroxymethyl-2P-furyl) indazole, YC-1 [37,38], has been
employed to directly activate soluble guanylyl cyclase in a
clonal pancreatic L-cell line, BRIN-BD11, without the need
to generate intracellular NO. In addition, we have also inves-
tigated the expression of PKG isoforms in these cells and have
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employed a highly selective substrate analogue, Rp-8-pCPT-
cGMPS, as an inhibitor of PKG. The aim was to establish
whether activation of PKG underlies the pro-apoptotic ac-
tions of a rise in cGMP in L-cells.
2. Materials and methods
2.1. Materials
RPMI 1640, trypsin/EDTA, phosphate-bu¡ered saline (PBS), pen-
icillin and streptomycin were purchased from Invitrogen, UK. YC-1,
annexin-V-Cy3 apoptosis detection kit and propidium iodide were
from Sigma-Aldrich, UK. Rp-8-pCPT-cGMPS, Z-DEVD-fmk and
Z-VAD-fmk were purchased from Calbiochem, UK and RNase
(DNase-free) was from Roche, UK. cGMP Direct enzyme-linked im-
munosorbent assay (ELISA) kit was purchased from Amersham Bio-
sciences, UK. TACS DNA Laddering kit was purchased from RpD
Systems.
2.2. Growth and incubation of BRIN-BD11 cells
BRIN-BD11 L-cells [39] were seeded at a concentration of 105 cells
per well, in 6-well cell culture plates containing RPMI 1640 medium
supplemented with 10% foetal calf serum, 2 mM L-glutamine, penicil-
lin (400 IU/ml) and streptomycin sulphate (200 Wg/ml). The cells were
cultured at 37‡C (5% CO2) in the absence or presence of test reagents.
Stock solutions of all the reagents were prepared in dimethyl sulph-
oxide (DMSO) and the solvent was added to all control cultures.
2.3. Analysis of BRIN cell death
Cell death was analysed using light microscopy and £ow cytometry.
Following incubation with test reagents, the culture medium contain-
ing detached cells was harvested. Adherent cells were incubated with
trypsin/EDTA (0.5 ml per well) for 5 min at 37‡C and 2 ml of com-
plete culture medium was then added. The cells were collected by
centrifugation (300Ug ; 5 min) and the pellet resuspended in 150 Wl
of culture medium. 150 Wl of 0.2% trypan blue (in PBS) was added
and the number of dead cells counted using a haemocytometer. Ex-
periments were performed in duplicate and repeated on at least three
occasions.
For analysis of DNA fragmentation by £ow cytometry, cells were
harvested as above and resuspended in 200 Wl of PBS. The cells were
then ¢xed with ice-cold ethanol:PBS (70:30 v:v) for 30 min on ice.
After ¢xation, the cells were centrifuged for 5 min at 300Ug and
resuspended in 820 Wl of PBS. 80 Wl of propidium iodide (0.5 mg/
ml) and 5 Wl of DNase-free ribonuclease were then added and incu-
bation continued for 30 min at 37‡C. After this time, cellular DNA
was analysed using a £ow cytometer (FACScan, Becton Dickinson).
Flow cytometric analysis of L-cell apoptosis was performed by an-
nexin-V-Cy3 staining. Following incubation with test reagents, cells
were harvested and washed twice with PBS before resuspension at 106
cells/ml. 500 Wl of this suspension was removed and 5 Wl of annexin-V-
Cy3 added. The cells were incubated for 10 min at room temperature
and then analysed by £ow cytometry.
2.4. DNA laddering
For the detection of DNA laddering, a TACS DNA Laddering kit
(RpD Systems) was used according to the manufacturer’s protocol.
DNA was isolated from both adherent and non-adherent cells after
incubation with test reagents and was electrophoresed on 1.5% aga-
rose gels. Gels were post-stained for 15 min in 0.5 mg/ml ethidium
bromide and visualised using a UV transilluminator.
2.5. Measurement of cGMP levels
BRIN cell cGMP levels were measured using a cGMP ELISA kit
(Amersham Biosciences, UK) according to the manufacturer’s instruc-
tions. Cells were cultured in 96-well plates then lysed by addition of
5% dodecyltrimethylammonium bromide. Samples were stored at
320‡C prior to measurement of cGMP by reference to appropriate
standards run in parallel.
2.6. RT-PCR analysis of PKG expression in BRIN-BD11 cells
Total RNA was extracted from BRIN cells with Trizol reagent and
was ampli¢ed by reverse transcription polymerase chain reaction (RT-
PCR) in a single tube reaction (Abgene, UK) using primers designed
against sequences of the human PKG isoforms. The primer sequences
were: PKG-IK : F-tgccaagattctcatgctca, R-ggaaggacctgtacgtctgc;
PKG-IL : F-caccttgcgggatttacagt, R-gatcaccgagcggtacttgt, PKG II:
F-aagcacccagatggacactc, R-tggatgcacttgttctggag. Cycling conditions
(30 cycles) were 94‡C for 60 s, 56‡C for 60 s, 72‡C for 60 s. Products
were separated on agarose gels then extracted and subcloned into
Topo-2 vectors (Promega, UK) for DNA sequencing.
2.7. Statistical analysis
Statistical analysis was performed by Student’s t-test or by analysis
of variance, and results were considered signi¢cant when P6 0.05.
3. Results
3.1. E¡ects of YC-1 on the viability of BRIN-BD11 cells
Initially, it was important to establish whether exposure of
BRIN-BD11 (BRIN) cells to the guanylyl cyclase activator,
YC-1, resulted in loss of viability. Cells were treated with
either YC-1 (25 and 100 WM) or vehicle (DMSO) for up to
72 h and the extent of cell death monitored by vital dye
staining (Fig. 1A). Control cells remained viable throughout
the experiment whereas cells exposed to YC-1 progressively
lost viability. This e¡ect was most pronounced with the higher
concentration of YC-1 where exposure for as little as 24 h
resulted in the death of more than 50% of the cells. A similar
loss of viability was also achieved with 25 WM YC-1, but this
response required a longer period of incubation (72 h). Ex-
amination of the dose^response curve for induction of cell
death (Fig. 1B) revealed an EC50 of approximately 40 WM
for YC-1. Con¢rmation that the mode of cell death involved
induction of apoptosis was provided by an examination of the
surface labeling of phosphatidylserine with annexin-V (Fig.
1C). Cells incubated under control conditions were largely
negative for annexin-V, whereas exposure to YC-1 for 24 h
resulted in a large increase in annexin-V-positive cells, consis-
tent with the entry of these cells into the apoptotic pathway.
3.2. Involvement of cGMP and the PKG pathway in mediating
the e¡ects of YC-1 in BRIN-BD11 cells
In order to con¢rm that YC-1 induces a rise in cGMP in
BRIN cells, direct measurements were made of cGMP levels
following exposure of cells to increasing concentrations of the
compound (Fig. 2). A detectable rise in cGMP was elicited by
as little as 6 WM YC-1 and the level increased progressively as
the concentration was raised, such that, at 100 WM, cGMP
was increased more than eight-fold above control.
There is currently no information on the expression of PKG
isoforms in L-cells and we considered it important to establish
this before attempting to assess the involvement of PKG in
mediating the pro-apoptotic e¡ects of YC-1. Accordingly,
RNA was extracted and ampli¢ed by RT-PCR to investigate
the expression of the three known isoforms of PKG, IK, IL
and II. As the full sequences of all three enzymes were not
available for rat, we used primers directed to regions of the
appropriate human sequence. These ampli¢ed products of the
correct size for all three isoforms in BRIN cells (Fig. 3A) and
direct sequence analysis con¢rmed that these were more than
90% identical with the equivalent human PKG sequence, in
each case. Thus, we conclude that BRIN-BD11 cells express
transcripts for all three isoforms of PKG. In order to con¢rm
that this re£ects the situation in primary islet cells, RNA was
also extracted from two separate batches of isolated human
islets and ampli¢ed by RT-PCR. Again, all three PKG iso-
forms were successfully ampli¢ed (not presented).
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Having established that BRIN cells express PKG, the ef-
fects of a highly selective PKG inhibitor (Rp-8-pCPT-cGMPS
[40]) on YC-1-induced cell death, were investigated (Fig. 3B).
Rp-8-pCPT-cGMPS signi¢cantly attenuated the loss of viabil-
ity caused by YC-1, which was reduced by more than 50% in
the presence of the inhibitor (Fig. 3B).
3.3. Mode of cell death induced by YC-1 in BRIN-BD11 cells
Measurement of annexin-V staining revealed that treatment
of BRIN cells with YC-1 was associated with phosphatidyl-
serine translocation (Fig. 1C) consistent with induction of ap-
optosis. However, pre-incubation of the cells with the cell-
permeable caspase 3 inhibitor, Z-DEVD-fmk, failed to im-
prove the viability of cells exposed to YC-1 (Fig. 3C). Similar
results were also obtained when a lower concentration of YC-
1 was used (25 WM) or when a di¡erent caspase inhibitor
having less restricted speci¢city (Z-VAD-fmk) was employed
(not shown).
In view of these ¢ndings, the e¡ects of YC-1 on DNA
fragmentation in BRIN cells were studied by £ow cytometry
and gel electrophoresis. Flow cytometric analysis con¢rmed
that cells exposed to YC-1 contained fragmented DNA. In
four separate experiments, the sub-diploid DNA peak was
increased from a mean of 9.7 S 1.6% in control cells to
33.5S 3.3% after 18 h exposure to 100 WM YC-1
(P6 0.001). Despite this, analysis of DNA fragmentation in
YC-1-treated cells by gel electrophoresis failed to reveal evi-
dence of the pattern of oligonucleosomal DNA fragmentation
characteristic of caspase-dependent apoptosis (Fig. 4). For
comparison, cells were also exposed to 5 mM NaF and, as
expected from previous studies [41], this did result in oligonu-
cleosomal DNA fragmentation (Fig. 4).
To explore further the implications of these phenomena,
Fig. 2. E¡ect of YC-1 on cGMP levels in BRIN cells. BRIN cells
were treated with increasing concentrations of YC-1 for 6 h then ex-
tracted for measurement of cGMP by ELISA. Each point is the
mean of duplicate cell incubations. The experiment was repeated
twice with similar results.
6
Fig. 1. Induction of cell death in BRIN-BD11 cells by YC-1. A:
BRIN cells were cultured in the absence (squares) or presence of ei-
ther 25 WM YC-1 (circles) or 100 WM YC-1 (triangles) for the time
periods shown. After incubation, the cells were harvested and
stained with trypan blue to monitor viability. Each point represents
the mean of duplicate determinations from a single experiment that
was repeated twice with similar results. B: BRIN cells were exposed
to increasing concentrations of YC-1 for 48 h then analysed by £ow
cytometry. Each point is the mean of duplicate determinations from
a single experiment that was repeated twice with similar results. C:
BRIN cells were treated with 100 WM YC-1 overnight then stained
with annexin-V-Cy3 and analysed by £ow cytometry. Results repre-
sent mean values ( S S.E.M.) from four separate experiments.
*P6 0.001 relative to control cells.
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additional experiments were performed in which BRIN cells
were treated with the protein synthesis inhibitor, actinomycin
D. This agent promotes the loss of viability in many cell types
[42^44] but, despite this, it has also been reported to attenuate
the cytotoxic e¡ects of compounds acting via ‘atypical’ path-
ways of programmed cell death [45].
Treatment of BRIN-BD11 cells with actinomycin D re-
sulted in a dose-dependent reduction in viability at concen-
trations up to 1 WM (Fig. 5). Vital dye staining revealed that
this response was sensitive to inhibition by Z-DEVD-fmk (0.5
Wg/ml actinomycin-23.0 S 1.7% dead cells; actinomycin+10
WM Z-DEVD-fmk-16.8 S 0.8%; P6 0.01). Strikingly, it was
observed that simultaneous exposure of BRIN cells to both
actinomycin D and YC-1 was associated with a mutually an-
tagonistic inhibition of cell death (Fig. 5). Thus, when the
drugs were used in combination, the viability of the cells
was maintained at much higher levels than when either com-
pound was applied alone.
4. Discussion
Considerable progress has been made in de¢ning the ‘down-
stream’ e¡ectors involved in regulating L-cell apoptosis,
whereas the more proximal, ‘upstream’, signalling events are
much less well characterised. However, these are likely to be
critically important to L-cell viability and an understanding of
their regulation may o¡er the opportunity for therapeutic in-
tervention to minimise L-cell loss in diabetes.
In the present work we have evaluated the previous sugges-
tion [17,27,28] that changes in cGMP may be important for
determining the viability of pancreatic L-cells. This conclusion
was originally derived from studies performed with chemical
NO donors which promote an increase in cGMP indirectly, by
raising the concentration of intracellular NO [17,27]. Some of
this NO then interacts with the haem group of soluble gua-
nylyl cyclase, leading to activation of the enzyme and a rise in
cGMP [27,28]. However, although NO donors are e¡ective in
raising cGMP [46], the time course of the response can be very
short-lived and the interpretation of results is complicated by
the fact that NO can exert a range of other detrimental e¡ects
that are independent of cGMP [31^33]. Moreover, in one re-
port, it was suggested that a rise in cGMP (which was as-
sumed to derive from exposure of islets to carbon monoxide)
might be protective to L-cells [47]. Therefore, in the current
study, we have exploited the potential of a structurally di¡er-
ent compound, YC-1, that binds directly to guanylyl cyclase
and elevates cGMP without requiring the intermediacy of a
rise in NO [37,38].
Treatment of BRIN-BD11 cells with YC-1 caused a dose-
dependent increase in cGMP (Fig. 2) con¢rming that the solu-
ble form of guanylyl cyclase expressed in BRIN cells is sensi-
tive to this reagent. In addition, YC-1 also caused a time- and
dose-dependent loss of BRIN cell viability, which is consistent
with the proposition that cGMP may play a role in regulating
the viability of these cells independently of NO formation. It
should be noted, however, that YC-1 may also cause cell
death by cGMP-independent mechanisms in some cell types
[48]. Firm evidence that this was not the case in the present
work was provided by the results of experiments with Rp-8-
pCPT-cGMPS. This compound is a highly selective inhibitor
of PKG [40] and the ¢nding that a low concentration (0.5
WM) markedly attenuated the response to YC-1 is consistent
Fig. 3. Involvement of PKG and caspases in YC-1-induced cell death. A: PKG isoform expression in BRIN cells was determined by RT-PCR
after extraction of total RNA. Ampli¢ed bands corresponding to PKG-IK, -IL and II were separated on agarose gels and visualised with ethid-
ium bromide under UV illumination. The identity of each band was con¢rmed by DNA sequencing. B: BRIN cells were incubated under con-
trol conditions or with 25 WM YC-I in the absence (grey bar) or presence (hatched bar) of 0.5 WM Rp-8-pCTP-cGMPS. 24 h later the cells
were harvested and stained with trypan blue to monitor viability. Each point is the mean (S S.E.M.) from four separate experiments. C: BRIN
cells were incubated under control conditions or with 100 WM YC-1 in the absence (grey bar) or presence (hatched bar) of 50 WM Z-DEVD-
fmk. Cells were treated with the caspase inhibitor 2 h prior to addition of YC-1. Following incubation for a further 24 h, cells were harvested
and analysed by £ow cytometry. Each point is the mean (S S.E.M.) from three separate experiments. *P6 0.01 relative to YC-1 alone.
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with the conclusion that at least part of the induction of cell
death was secondary to activation of PKG by cGMP.
In drawing this conclusion it is important to note that the
expression of PKG has been investigated to only a very lim-
ited extent in L-cells and that, although PKG activity has been
measured [27], there are no data on the pattern of isoform
expression in these cells. Accordingly, we examined PKG ex-
pression by RT-PCR and observed that all three known iso-
forms, PKG-IK, -IL and -II, are present. Similar results were
obtained both in clonal BRIN cells and in primary human
islets, suggesting that all three isoforms are likely to be ex-
pressed in the L-cells in vivo. The respective roles of these
enzymes remain to be established but it seems probable that
the signals arising from a rise in cGMP will be transduced
di¡erentially according to the subcellular localisation and sub-
strate availability of each isoform. Nevertheless, the results
suggest that at least one isoform is involved in controlling
L-cell viability.
The proposal that PKG activation may mediate the e¡ects
of cGMP on L-cell viability was originally advanced on the
basis of data obtained with the inhibitor, KT5823 [17,27,28].
However, the e⁄cacy and speci¢city of this compound have
recently been questioned [35] and it has even been suggested
that its functional activity might be attributable to the pres-
ence of an unidenti¢ed contaminant [36]. Thus, the present
results employing a more potent and highly selective substrate
analogue as an inhibitor of PKG provide important con¢rma- tion that the enzyme is involved in mediating the pro-apopto-
tic e¡ects of cGMP in L-cells.
Analysis of YC-1-treated BRIN cells by annexin-V staining
revealed that the compound promotes a marked increase in
the number of positively stained cells. Annexin-V labels phos-
phatidylserine, a lipid that is normally localised within the
inner lea£et of the plasma membrane but which becomes
translocated across the bilayer during the early stages of ap-
optosis [49]. Thus, these results imply that YC-1 elevates
cGMP and thereby leads to the activation of PKG and the
entry of BRIN cells into apoptosis. The time course and dose^
response data (Figs. 1 and 2) suggest that a modest, acute
elevation of cGMP may not be su⁄cient to elicit this response
but that a more sustained elevation is required. Thus, it is
probable that both temporal (time course of cGMP elevation)
and spatial (subcellular distribution of PKG and its sub-
strates) e¡ects are important in determining the outcome of
PKG activation. Indeed, it is even conceivable that the e¡ects
of cGMP may be di¡erentially anti- [47] or pro-apoptotic [17]
according to the time course and magnitude of the response.
Despite the evidence that YC-1 causes BRIN cells to enter
apoptosis, the response was not sensitive to blockade by either
a selective inhibitor of the e¡ector caspase, caspase 3 (Z-
DEVD), nor by the pan-caspase inhibitor, Z-VAD. Thus, it
appears that PKG-mediated cell death may occur by a path-
way that does not require caspase activation, in BRIN cells.
In support of this, it was also discovered that the induction of
cell death by YC-1 occurred without any increase in oligonu-
cleosomal DNA fragmentation (Fig. 4), a process that nor-
mally accompanies caspase-dependent activation of apoptosis
[45]. We also examined caspase activation using £uorescent
substrates in BRIN cells treated with YC-1 and, again, ob-
served no marked increase in response to the agent (A. Ka-
minski and N.G. Morgan, unpublished).
Taken together, these results imply that PKG activation
mediates a pathway of L-cell death that occurs independently
Fig. 5. E¡ects of actinomycin D on YC-I-induced cell death in
BRIN cells. BRIN cells were incubated in the absence (squares) or
presence (circles) of 100 WM YC-1 and increasing concentrations of
actinomycin D, as shown. Following incubation for 24 h, cells were
harvested and their viability monitored. Each point represents the
meanSS.E.M. from triplicate experiments. *P6 0.001 relative to
control cells incubated in the absence of YC-1. **P6 0.001 relative
to control cells incubated in the absence of actinomycin D.
***P6 0.01 relative to cells incubated with YC-1 or actinomycin D
alone.
Fig. 4. Gel electrophoresis of DNA extracted from BRIN cells.
BRIN cells were incubated under control conditions (lane 2) or in
the presence of either 100 WM YC-1 (lane 3) or 5 mM NaF (lane 4)
for 24 h. DNA was then extracted from the cells, separated by elec-
trophoresis on agarose gels and visualised by staining with ethidium
bromide. Marker DNA was run in parallel in lane 1.
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of caspase activation but which leads to phosphatidylserine
translocation and loss of high molecular weight DNA (as
revealed by £ow cytometry). Thus, these ¢ndings raise the
possibility that YC-1 (and, hence, cGMP and PKG activa-
tion) elicits a mode of programmed cell death that di¡ers
from ‘classical’ apoptosis in L-cells [45]. As such, the results
are in accord with the studies of Tejedo et al. [27] who re-
ported that cGMP-induced cell death in RINm5F L-cells is
not mediated by a typical apoptotic mechanism even though it
is accompanied by certain features that accompany pro-
grammed cell death.
This proposition is supported most clearly by the outcome
of experiments performed with actinomycin D. This reagent is
unusual in that it has the ability to induce caspase activation
and cell death in some cells (including BRIN cells, as shown
here) while also inhibiting certain alternative, transcription-
dependent, pathways of programmed cell death [45]. Strik-
ingly, despite causing extensive cell death itself, actinomycin
D dramatically attenuated the extent of cell death in cells
exposed to YC-1 (Fig. 5). Thus, the two drugs exerted mu-
tually antagonistic e¡ects, consistent with the induction of a
pathway of programmed cell death in each case.
Further studies will be required to understand the molec-
ular mechanisms involved in the pathway of programmed cell
death induced by cGMP and PKG, but there is evidence that
down-regulation of Bcl-2 expression occurs as a consequence
of PKG activation in L-cells [27]. Whether this is a primary
event mediating the loss of cell viability or whether it follows
as a secondary consequence of more fundamental changes
remains to be established. Nevertheless, the present ¢ndings
are consistent with the proposal that sustained PKG activa-
tion, mediated by a rise in cGMP, provides a signal to activate
programmed cell death in L-cells.
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